Autopsy report · NCT02621190

Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs

“no approval”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Erasmus Medical Center

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms

Interventions

cabazitaxel

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design"
  “no approval by CA” (72% match in meaning)
• Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients
  “Regulatory approvals have not been obtained” (68% match in meaning)
• Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU
  “No MEC approval” (68% match in meaning)
• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
  “No approval from ethical committee” (62% match in meaning)
• Vascularized Composite Bladder Allograft Transplantation
  “pending UNOS approval” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.